BiotechTube
Eikon Therapeutics

Eikon Therapeutics

EIKN
United States

Eikon Therapeutics is a next-generation drug discovery company founded by Nobel laureate Dr. Eric Betzig, leveraging breakthrough single-molecule tracking microscopy and AI to visualize and quantify protein movement within living cells. This unique platform aims to identify novel drug targets and develop small molecule therapeutics for complex diseases, particularly in oncology. The company has attracted substantial venture capital and strategic investment, reflecting strong confidence in its technology and approach to tackling historically intractable biological pathways.

eikontx.com

EIKN · Stock Price

USD 11.063.94 (-26.27%)
Market Cap: $626.8M

Historical price data

AI Company Overview

Eikon Therapeutics is a next-generation drug discovery company founded by Nobel laureate Dr. Eric Betzig, leveraging breakthrough single-molecule tracking microscopy and AI to visualize and quantify protein movement within living cells. This unique platform aims to identify novel drug targets and develop small molecule therapeutics for complex diseases, particularly in oncology. The company has attracted substantial venture capital and strategic investment, reflecting strong confidence in its technology and approach to tackling historically intractable biological pathways.

OncologyImmunology

Technology Platform

A proprietary drug discovery platform combining Nobel Prize-winning super-resolution microscopy for single-molecule tracking in living cells with advanced machine learning and AI to visualize and quantify protein dynamics, enabling the identification of novel drug targets and mechanisms.

Pipeline

5
5 drugs in pipeline
DrugIndicationStageWatch
BDB001Tumor, SolidPhase 2
EIK1001 + Pembrolizumab + Paclitaxel + Pemetrexed + Carbopla...NSCLCPhase 2
EIK1004-001 (IMP1707-001)Advanced Solid TumorsPhase 1/2
IMP1734Advanced Solid TumorPhase 1/2
BDB001 (EIK1001) + AtezolizumabTumor, SolidPhase 1

Funding History

2
Total raised:$665.8M
Series B$517.8MJan 15, 2022
Series A$148MOct 15, 2021

Opportunities

The primary opportunity is to validate a new drug discovery paradigm and bring first-in-class therapeutics to market in high-need areas like oncology.
Success could lead to platform expansion into neuroscience, metabolic diseases, and other areas driven by complex protein dynamics.
The company is also well-positioned for strategic partnerships or acquisition by large pharma seeking to access its novel platform and pipeline.

Risk Factors

Key risks include the unproven clinical translation of its platform technology, the significant technical challenges of scaling a complex microscopy and AI system, intense competition in AI-driven drug discovery, and the inherent high failure rates of drug development.
The company's high valuation also creates pressure to deliver exceptional results.

Competitive Landscape

Eikon competes with AI/ML-driven drug discovery platforms like Recursion and Exscientia, though its core data from single-molecule tracking is unique. In oncology therapeutics, it faces competition from all major pharmaceutical companies. Its main differentiation is the direct, functional measurement of protein dynamics in living cells, a capability not replicated at scale by competitors.